Erratum: Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice (Diabetologia DOI: 10.1007/s00125-011-2055-2);Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice

Diabetologia

Volumn 54, Issue 5, 2011, Pages 1252-1260

  Yoon, J ^a,b   Subramanian, S ^a   Ding, Y ^a   Wang, S ^a   Goodspeed, L ^a   Sullivan, B ^a   Kim, J ^a   O'Brien, K D ^a   Chait, A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

Adipose tissue; Atherosclerosis; Hyperglycaemia; Inflammation; Insulin; Macrophage; Mouse; Obesity

Indexed keywords

CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; INSULIN DETEMIR; INSULIN GLARGINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; SERUM AMYLOID P; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; HYPERGLYCEMIA; INSULIN TREATMENT; INTRAABDOMINAL FAT; LONG TERM CARE; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 79954627979     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2156-y     Document Type: Erratum

References (47)

1. SP Weisberg D McCann M Desai M Rosenbaum RL Leibel AW Ferrante Jr 2003 Obesity is associated with macrophage accumulation in adipose tissue J Clin Invest 112 1796 1808 14679176 1:CAS:528:DC%2BD3sXhtVSmtLvO (Pubitemid 38063703)
2. S Subramanian CY Han T Chiba, et al. 2008 Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 28 685 691 18239153 10.1161/ATVBAHA.107.157685 1:CAS:528:DC%2BD1cXjt1Slt74%3D (Pubitemid 351651333)
3. H Xu GT Barnes Q Yang, et al. 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 112 1821 1830 14679177 1:CAS:528:DC%2BD3sXhtVSmtLvI (Pubitemid 38063705)
4. MC Arkan AL Hevener FR Greten, et al. 2005 IKK-beta links inflammation to obesity-induced insulin resistance Nat Med 11 191 198 15685170 10.1038/nm1185 1:CAS:528:DC%2BD2MXpvF2mtQ%3D%3D (Pubitemid 40321355)
5. GS Hotamisligil NS Shargill BM Spiegelman 1993 Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance Science 259 87 91 7678183 10.1126/science.7678183 1:CAS:528:DyaK3sXnvFaitw%3D%3D (Pubitemid 23036092)
6. GS Hotamisligil DL Murray LN Choy BM Spiegelman 1994 Tumor necrosis factor alpha inhibits signaling from the insulin receptor Proc Natl Acad Sci USA 91 4854 4858 8197147 10.1073/pnas.91.11.4854 1:CAS:528:DyaK2cXktVOiurY%3D (Pubitemid 24177748)
7. GS Hotamisligil 2006 Inflammation and metabolic disorders Nature 444 860 867 17167474 10.1038/nature05485 1:CAS:528:DC%2BD28XhtlShtrzK (Pubitemid 46024993)
8. CM Eklund 2009 Proinflammatory cytokines in CRP baseline regulation Adv Clin Chem 48 111 136 19803417 10.1016/S0065-2423(09)48005-3 1:CAS:528: DC%2BD1MXhs1Wis7bF
9. CM Uhlar AS Whitehead 1999 Serum amyloid A, the major vertebrate acute-phase reactant Eur J Biochem 265 501 523 10504381 10.1046/j.1432-1327. 1999.00657.x 1:CAS:528:DyaK1MXmslGlt7k%3D (Pubitemid 29488982)
10. AA Manfredi P Rovere-Querini B Bottazzi C Garlanda A Mantovani 2008 Pentraxins, humoral innate immunity and tissue injury Curr Opin Immunol 20 538 544 18579363 10.1016/j.coi.2008.05.004 1:CAS:528:DC%2BD1cXhtVyltbbE
11. WT Cefalu S Werbel AD Bell-Farrow, et al. 1998 Insulin resistance and fat patterning with aging: relationship to metabolic risk factors for cardiovascular disease Metabolism 47 401 408 9550536 10.1016/S0026-0495(98) 90050-6 1:CAS:528:DyaK1cXitlygtbw%3D (Pubitemid 28180944)
12. BD Johnson KE Kip OC Marroquin, et al. 2004 Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Circulation 109 726 732 14970107 10.1161/01.CIR.0000115516. 54550.B1 1:CAS:528:DC%2BD2cXhtFWltbs%3D (Pubitemid 38222891)
13. P Libby PM Ridker 2004 Inflammation and atherosclerosis: role of C-reactive protein in risk assessment Am J Med 116 Suppl 6A 9S 16S 15050187 10.1016/j.amjmed.2004.02.006 (Pubitemid 38402010)
14. PM Ridker CH Hennekens JE Buring N Rifai 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 836 843 10733371 10.1056/NEJM200003233421202 1:CAS:528:DC%2BD3cXisVensrs%3D (Pubitemid 30165206)
15. P Dandona A Chaudhuri P Mohanty H Ghanim 2007 Anti-inflammatory effects of insulin Curr Opin Clin Nutr Metab Care 10 511 517 17563472 10.1097/MCO.0b013e3281e38774 1:CAS:528:DC%2BD2sXotl2lt78%3D (Pubitemid 46934123)
16. H Ghanim K Korzeniewski CL Sia, et al. 2010 Suppressive effect of insulin infusion on chemokines and chemokine receptors Diabetes Care 33 1103 1108 20200310 10.2337/dc09-2193 1:CAS:528:DC%2BC3cXnsFyltr4%3D
17. P Dandona A Aljada P Mohanty H Ghanim A Bandyopadhyay A Chaudhuri 2003 Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9 Diabetes Care 26 3310 3314 14633819 10.2337/diacare.26.12.3310 1:CAS:528:DC%2BD3sXpvF2ksL8%3D (Pubitemid 37466892)
18. T Albacker G Carvalho T Schricker K Lachapelle 2008 High-dose insulin therapy attenuates systemic inflammatory response in coronary artery bypass grafting patients Ann Thorac Surg 86 20 27 18573392 10.1016/j.athoracsur.2008. 03.046
19. MG Carlson PJ Campbell 1993 Intensive insulin therapy and weight gain in IDDM Diabetes 42 1700 1707 8243815 10.2337/diabetes.42.12.1700 1:STN:280:DyaK2c%2Fmtlantw%3D%3D (Pubitemid 23346405)
20. SI McFarlane 2009 Insulin therapy and type 2 diabetes: management of weight gain J Clin Hypertens (Greenwich) 11 601 607 10.1111/j.1751-7176.2009. 00063.x 1:CAS:528:DC%2BD1MXhsVeqs7vN
21. D Russell-Jones R Khan 2007 Insulin-associated weight gain in diabetes-causes, effects and coping strategies Diabetes Obes Metab 9 799 812 17924864 10.1111/j.1463-1326.2006.00686.x 1:CAS:528:DC%2BD2sXhtlOlsLvL (Pubitemid 47555203)
22. E Leinonen E Hurt-Camejo O Wiklund LM Hulten A Hiukka MR Taskinen 2003 Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes Atherosclerosis 166 387 394 12535753 10.1016/S0021-9150(02)00371-4 1:CAS:528:DC%2BD3sXjt1WhtA%3D%3D (Pubitemid 36071698)
23. RZ Yang MJ Lee H Hu, et al. 2006 Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications PLoS Med 3 e287 16737350 10.1371/journal.pmed.0030287 (Pubitemid 43987831)
24. LR Tannock KD O'Brien RH Knopp, et al. 2005 Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects Circulation 111 3058 3062 15939816 10.1161/CIRCULATIONAHA.104.506188 1:CAS:528:DC%2BD2MXkvVCmu78%3D (Pubitemid 40847782)
25. DA Schaumberg RJ Glynn AJ Jenkins, et al. 2005 Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial Circulation 111 2446 2453 15867184 10.1161/01.CIR.0000165064.31505.3B 1:CAS:528:DC%2BD2MXjvFOis74%3D (Pubitemid 40696132)
26. PM Ridker JE Buring NR Cook N Rifai 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women Circulation 107 391 397 12551861 10.1161/01.CIR.0000055014.62083.05
27. KE Lewis EA Kirk TO McDonald, et al. 2004 Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice Circulation 110 540 545 15277327 10.1161/01.CIR.0000136819.93989.E1 1:CAS:528:DC%2BD2cXlvF2htLg%3D (Pubitemid 39031170)
28. T Chiba CY Han T Vaisar, et al. 2009 Serum amyloid A3 does not contribute to circulating SAA levels J Lipid Res 50 1353 1362 19286646 10.1194/jlr.M900089-JLR200 1:CAS:528:DC%2BD1MXnslSltrs%3D
29. J Folch M Lees GH Sloane-Stanley 1957 A simple method for the isolationand purification of total lipids from animal tissues J Biol Chem 226 497 509 13428781 1:STN:280:DyaG2s%2FnsFCjtw%3D%3D
30. CY Han S Subramanian CK Chan, et al. 2007 Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion Diabetes 56 2260 2273 17563062 10.2337/db07-0218 1:CAS:528:DC%2BD2sXhtV2gs7bE (Pubitemid 47358233)
31. I Murano G Barbatelli V Parisani, et al. 2008 Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice J Lipid Res 49 1562 1568 18390487 10.1194/jlr.M800019-JLR200 1:CAS:528:DC%2BD1cXotVOqu7Y%3D
32. K Samaras NK Botelho DJ Chisholm RV Lord 2010 Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes Obesity (Silver Spring) 18 884 889 10.1038/oby.2009.443 1:CAS:528: DC%2BC3cXlt1ahsbY%3D
33. MK Ohman Y Shen CI Obimba, et al. 2008 Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice Circulation 117 798 805 18212290 10.1161/CIRCULATIONAHA.107.717595 (Pubitemid 351640681)
34. AJ Szalai MA McCrory 2002 Varied biologic functions of C-reactive protein: lessons learned from transgenic mice Immunol Res 26 279 287 12403365 10.1385/IR:26:1-3:279 1:CAS:528:DC%2BD38Xos1CisL8%3D (Pubitemid 35177504)
35. LR Reynolds FJ Kingsley DG Karounos LR Tannock 2007 Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes Diabetes Res Clin Pract 77 180 187 17239474 10.1016/j.diabres.2006.12.011 1:CAS:528:DC%2BD2sXkvFGjs7w%3D (Pubitemid 46670418)
36. AD Pradhan BM Everett NR Cook N Rifai PM Ridker 2009 Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial Jama 302 1186 1194 19755697 10.1001/jama.2009.1347 1:CAS:528:DC%2BD1MXhtFCitb3K
37. VA Fonseca P Theuma S Mudaliar CA Leissinger S Clejan RR Henry 2006 Diabetes treatments have differential effects on nontraditional cardiovascular risk factors J Diabetes Complications 20 14 20 16389162 10.1016/j.jdiacomp.2005. 05.009 (Pubitemid 43028408)
38. AM Aas I Seljeflot PA Torjesen LM Diep PM Thorsby KI Birkeland 2006 Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes Diabetologia 49 872 880 16555056 10.1007/s00125-006-0205-8 1:CAS:528: DC%2BD28XjvFWrtLs%3D
39. JQ Purnell RK Dev MW Steffes, et al. 2003 Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial Diabetes 52 2623 2629 14514648 10.2337/diabetes.52.10.2623 1:CAS:528:DC%2BD3sXotVWhsbk%3D (Pubitemid 37210553)
40. Y Wu JY Kim S Zhou CM Smas 2008 Differential screening identifies transcripts with depot-dependent expression in white adipose tissues BMC Genomics 9 397 18721461 10.1186/1471-2164-9-397
41. R Caesar M Manieri T Kelder, et al. 2010 A combined transcriptomics and lipidomics analysis of subcutaneous, epididymal and mesenteric adipose tissue reveals marked functional differences PLoS One 5 e11525 20634946 10.1371/journal.pone.0011525
42. CT Montague JB Prins L Sanders, et al. 1998 Depot-related gene expression in human subcutaneous and omental adipocytes Diabetes 47 1384 1391 9726225 10.2337/diabetes.47.9.1384 1:CAS:528:DyaK1cXls12rs7Y%3D (Pubitemid 28396940)
43. C Fajardo Montanana C Hernandez Herrero M Rivas Fernandez 2008 Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial Diabet Med 25 916 923 18959604 10.1111/j.1464-5491.2008.02483.x 1:STN:280:DC%2BD1cnpsFSnsw%3D%3D
44. M Marre M Pinget H Gin, et al. 2009 Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE Study in a cohort of French patients with type 1 or type 2 diabetes Diabetes Metab 35 469 475 19914118 10.1016/j.diabet.2009.06.004 1:CAS:528:DC%2BC3cXhs1Klu7o%3D
45. I De Leeuw P Vague JL Selam, et al. 2005 Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin Diabetes Obes Metab 7 73 82 15642078 10.1111/j.1463-1326.2004.00363.x
46. BJ Van Lenten AC Wagner M Navab, et al. 2007 Lipoprotein inflammatory properties and serum amyloid a levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits J Lipid Res 48 2344 2353 17693626 10.1194/jlr.M700138-JLR200 (Pubitemid 350058746)
47. T Wada M Azegami M Sugiyama H Tsuneki T Sasaoka 2008 Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin Diabetes Res Clin Pract 81 269 277 18585815 10.1016/j.diabres.2008.05.007 1:CAS:528:DC%2BD1cXhtVWitLbJ